Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11548099 | 0.85 | GAA (0.67) | GAAKDM4EPOLBBRD4PTGDR2 | |
| Bromide SCHEMBL29103135 | 0.85 | GAA (0.62) | GAAKDM4EPOLBBRD4PTGDR2 | |
| SCHEMBL5018862 | 0.82 | GAA (0.59) | GAAKDM4EPOLBBRD4PTGDR2 | |
| SCHEMBL19231119 | 0.82 | GAA (0.54) | GAAKDM4EPOLBBRD4PTGDR2 | |
| SCHEMBL509015 | 0.81 | PTGDR2 (0.81) | GAAPOLBPTGDR2 | |
| SCHEMBL12281117 | 0.80 | KDM4E (0.69) | GAAKDM4EPOLBBRD4PTGDR2 | |
| SCHEMBL4006704 | 0.80 | POLB (0.58) | GAAKDM4EPOLBPTGDR2NPC1 | |
| SCHEMBL11242635 | 0.78 | GAA (0.62) | GAAPOLBPTGDR2NPC1LMNA | |
| SCHEMBL23402993 | 0.77 | KDM4E (0.65) | GAAKDM4EPOLBBRD4PTGDR2 | |
| SCHEMBL28355094 | 0.77 | KDM4E (0.65) | GAAKDM4EPOLBBRD4PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20080318957-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | GAA 67/4885KDM4E 3505/4885POLB 212/4885 |
| US-20080318957-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | GAA 67/4885KDM4E 3505/4885POLB 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.